Segall Bryant & Hamill LLC Acquires 41,739 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN)

Segall Bryant & Hamill LLC grew its stake in shares of Myriad Genetics, Inc. (NASDAQ:MYGN) by 137.4% during the fourth quarter, Holdings Channel reports. The institutional investor owned 72,117 shares of the company’s stock after purchasing an additional 41,739 shares during the quarter. Segall Bryant & Hamill LLC’s holdings in Myriad Genetics were worth $989,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Point72 Hong Kong Ltd purchased a new stake in Myriad Genetics during the 3rd quarter valued at about $32,000. Point72 Asia Singapore Pte. Ltd. grew its holdings in shares of Myriad Genetics by 43.8% in the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 4,833 shares of the company’s stock worth $132,000 after purchasing an additional 1,471 shares during the last quarter. Blue Trust Inc. increased its stake in shares of Myriad Genetics by 14.1% in the fourth quarter. Blue Trust Inc. now owns 14,451 shares of the company’s stock worth $198,000 after buying an additional 1,788 shares during the period. Swiss National Bank increased its stake in shares of Myriad Genetics by 1.0% in the fourth quarter. Swiss National Bank now owns 178,600 shares of the company’s stock worth $2,449,000 after buying an additional 1,800 shares during the period. Finally, Bank of New York Mellon Corp raised its holdings in Myriad Genetics by 0.4% during the 4th quarter. Bank of New York Mellon Corp now owns 646,003 shares of the company’s stock valued at $8,857,000 after buying an additional 2,256 shares during the last quarter. Hedge funds and other institutional investors own 99.02% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on MYGN shares. StockNews.com upgraded shares of Myriad Genetics from a “hold” rating to a “buy” rating in a research report on Tuesday. Craig Hallum started coverage on Myriad Genetics in a report on Wednesday, February 12th. They set a “buy” rating and a $29.00 price target on the stock. UBS Group dropped their price objective on Myriad Genetics from $18.00 to $16.00 and set a “neutral” rating for the company in a report on Tuesday, February 25th. Raymond James reissued an “outperform” rating and set a $19.00 target price (down from $27.00) on shares of Myriad Genetics in a research note on Tuesday, February 25th. Finally, Leerink Partners lowered Myriad Genetics from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $30.00 to $21.00 in a research note on Monday, December 9th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, Myriad Genetics presently has an average rating of “Hold” and a consensus price target of $21.89.

Myriad Genetics Stock Performance

Shares of MYGN stock opened at $8.88 on Friday. The company has a current ratio of 1.90, a quick ratio of 1.73 and a debt-to-equity ratio of 0.05. The company’s fifty day moving average price is $11.76 and its 200-day moving average price is $16.57. The stock has a market cap of $810.82 million, a PE ratio of -6.83 and a beta of 1.79. Myriad Genetics, Inc. has a 12 month low of $8.70 and a 12 month high of $29.30.

Myriad Genetics (NASDAQ:MYGN) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.12). Myriad Genetics had a negative return on equity of 4.51% and a negative net margin of 14.09%. The business had revenue of $210.60 million during the quarter, compared to analysts’ expectations of $210.35 million. During the same quarter last year, the company posted ($0.12) EPS. On average, equities analysts expect that Myriad Genetics, Inc. will post -0.3 EPS for the current fiscal year.

About Myriad Genetics

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.